Sox2 expression in human stomach adenocarcinomas with gastric and gastric-and-intestinal-mixed phenotypes

Histopathology

Volumn 46, Issue 6, 2005, Pages 649-658

  Tsukamoto, Tetsuya ^a   Mizoshita, T ^a   Mihara, M ^b   Tanaka, H ^a   Takenaka, Y ^a   Yamamura, Y ^a   Nakamura, S ^a   Ushijima, T ^b   Tatematsu, M ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Cdx1; Cdx2; Gastric transcription factor; Gastric and intestinal mixed type; HMG box; Homeobox genes; Intestinal transcription factor; Sox2

Indexed keywords

HIGH MOBILITY GROUP B PROTEIN; MESSENGER RNA; MUCIN 5AC; MUCIN 6; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CDX1; TRANSCRIPTION FACTOR CDX2; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HOMEOBOX; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; STOMACH ADENOCARCINOMA;

ADENOCARCINOMA; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGB PROTEINS; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL NEOPLASMS; MICROFILAMENT PROTEINS; MUCINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 20644444118     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2005.02170.x     Document Type: Article

References (53)

1. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma: an attempt at a histo-clinical classification. Acta Pathol. Microbiol. Scand. 1965; 64: 31-49.
2. Nakamura K, Sugano H, Takagi K. Carcinoma of the stomach in incipient phase: its histogenesis and histological appearances. Gann 1968; 59: 251-258.
3. Sugano H, Nakamura K, Kato Y. Pathological studies of human gastric cancer. Acta Pathol Jpn 1982; 32 (Suppl. 2): 329-347.
4. Tatematsu M, Tsukamoto T, Inada K. Stem cells and gastric cancer: role of gastric and intestinal mixed intestinal metaplasia. Cancer Sci. 2003; 94: 135-141.
5. Correa P, Shiao YH. Phenotypic and genotypic events in gastric carcinogenesis. Cancer Res. 1994; 54: 1941s-1943s.
6. Kawachi H, Takizawa T, Eishi Y et al. Absence of either gastric or intestinal phenotype in microscopic differentiated gastric carcinomas. J. Pathol. 2003; 199: 436-446.
7. Tatematsu M, Furihata C, Katsuyama T et al. Gastric and intestinal phenotypic expressions of human signet ring cell carcinomas revealed by their biochemistry, mucin histochemistry, and ultrastructure. Cancer Res. 1986; 46: 4866-4872.
8. Tatematsu M, Ichinose M, Miki K, Hasegawa R, Kato T, Ito N. Gastric and intestinal phenotypic expression of human stomach cancers as revealed by pepsinogen immunohistochemistry and mucin histochemistry. Acta Pathol Jpn 1990; 40: 494-504.
9. Mizoshita T, Tsukamoto T, Inada K et al. Immunohistochemically detectable Cdx2 is present in intestinal phenotypic elements in early gastric cancers of both differentiated and undifferentiated types, with no correlation to non-neoplastic surrounding mucosa. Pathol. Int. 2004; 54: 392-400.
10. Tatematsu M, Furihata C, Katsuyama T et al. Independent induction of intestinal metaplasia and gastric cancer in rats treated with N-methyl-N′-nitro-N-nitrosoguanidine. Cancer Res. 1983; 43: 1335-1341.
11. Tatematsu M, Katsuyama T, Furihata C, Tsuda H, Ito N. Stable intestinal phenotypic expression of gastric and small intestinal tumor cells induced by N-methyl-N′-nitro-N-nitrosoguanidine or methylnitrosourea in rats. Gann 1984; 75: 957-965.
12. Tatematsu M, Katsuyama T, Fukushima S et al. Mucin histochemistry by paradoxical concanavalin A staining in experimental gastric cancers induced in Wistar rats by N-methyl-N-nitro-N-nitrosoguanidine or 4-nitroquinoline 1-oxide. J. Natl Cancer Inst. 1980; 64: 835-843.
13. Yuasa H, Hirano K, Kodama H et al. Immunohistochemical demonstration of intestinal-type alkaline phosphatase in stomach tumors induced by N-methyl-N′-nitro-N-nitrosoguanidine in rats. Jpn. J. Cancer Res. 1994; 85: 897-903.
14. Yuasa Y. Control of gut differentiation and intestinal-type gastric carcinogenesis. Nat. Rev. Cancer 2003; 3: 592-600.
15. Silberg DG, Sullivan J, Kang E et al. Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice. Gastroenterology 2002; 122: 689-696.
16. Silberg DG, Swain GP, Suh ER, Traber PG. Cdx1 and cdx2 expression during intestinal development. Gastroenterology 2000; 119: 961-971.
17. Mallo GV, Rechreche H, Frigerio JM et al. Molecular cloning, sequencing and expression of the mRNA encoding human Cdx1 and Cdx2 homeobox. Down-regulation of Cdx1 and Cdx2 mRNA expression during colorectal carcinogenesis. Int. J. Cancer 1997; 74: 35-44.
18. Mizoshita T, Inada K, Tsukamoto T et al. Expression of Cdx1 and Cdx2 mRNAs and relevance of this expression to differentiation in human gastrointestinal mucosa-with special emphasis on participation in intestinal metaplasia of the human stomach. Gastric Cancer 2001; 4: 185-191.
19. Mizoshita T, Inada K. Tsukamoto T et al. Expression of the intestine-specific transcription factors, Cdx1 and Cdx2, correlates shift to an intestinal phenotype in gastric cancer cells. J. Cancer Res. Clin. Oncol. 2004; 130: 29-36.
20. Mizoshita T, Tsukamoto T, Nakanishi H et al. Expression of Cdx2 and the phenotype of advanced gastric cancers: relationship with prognosis. J. Cancer Res. Clin. Oncol. 2003; 129: 727-734.
21. Bai Y, Akiyama Y, Nagasaki H et al. Distinct expression of CDX2 and GATA4/5, development-related genes, in human gastric cancer cell lines. Mol. Carcinog. 2000; 28: 184-188.
22. Bai YQ, Yamamoto H, Akiyama Y et al. Ectopic expression of homeodomain protein CDX2 in intestinal metaplasia and carcinomas of the stomach. Cancer Lett. 2002; 176: 47-55.
23. Seno H, Oshima M, Taniguchi MA et al. CDX2 expression in the stomach with intestinal metaplasia and intestinal-type cancer: prognostic implications. Int. J. Oncol. 2002; 21: 769-774.
24. Almeida R, Silva E, Santos-Silva F et al. Expression of intestine-specific transcription factors, CDX1 and CDX2, in intestinal metaplasia and gastric carcinomas. J. Pathol. 2003; 199: 36-40.
25. Eda A, Osawa H, Yanaka I et al. Expression of homeobox gene CDX2 precedes that of CDX1 during the progression of intestinal metaplasia. J. Gastroenterol. 2002; 37: 94-100.
26. Tsukamoto T, Inada K, Tanaka H et al. Down regulation of a gastric transcription factor. Sox2, and ectopic expression of intestinal homeobox genes, Cdx1 and Cdx2: inverse correlation during progression from gastric/intestinal- mixed to complete intestinal metaplasia. J. Cancer Res. Clin. Oncol. 2004; 130: 135-145.
27. Ishii Y, Rex M, Scotting PJ, Yasugi S. Region-specific expression of chicken Sox2 in the developing gut and lung epithelium: regulation by epithelial-mesenchymal interactions. Dev. Dyn. 1998; 213: 464-475.
28. Yasugi S. Epithelial cell differentiation during stomach development. Hum. Cell 2000; 13: 177-184.
29. Li XL, Eishi Y, Bai YQ et al. Expression of the SRY-related HMG box protein SOX2 in human gastric carcinoma. Int. J. Oncol. 2004; 24: 257-263.
30. Tsukamoto T, Fukami H, Yamanaka S et al. Hexosaminidase-altered aberrant crypts, carrying decreased hexosaminidase alpha and beta subunit mRNAs, in colon of 1,2-dimethylhydrazine-treated rats. Jpn J. Cancer Res. 2001; 92: 109-118.
31. Ho SB, Shekels LL, Toribara NW et al. Mucin gene expression in normal, preneoplastic, and neoplastic human gastric epithelium. Cancer Res. 1995; 55: 2681-2690.
32. Yamachika T, Inada K, Fujimitsu Y et al. Intestinalization of gastric signet ring cell carcinomas with progression. Virchows Arch. 1997; 431: 103-110.
33. Bamba M, Sugihara H, Kushima R. et al. Time-dependent expression of intestinal phenotype in signet ring cell carcinomas of the human stomach. Virchows Arch. 2001; 438: 49-56.
34. Yoshikawa A, Inada Ki K, Yamachika T, Shimizu N, Kaminishi M, Tatematsu M. Phenotypic shift in human differentiated gastric cancers from gastric to intestinal epithelial cell type during disease progression. Gastric Cancer 1998; 1: 134-141.
35. Silberg DG, Furth EE, Taylor JK, Schuck T, Chiou T, Traber PG. CDX1 protein expression in normal, metaplastic, and neoplastic human alimentary tract epithelium. Gastroenterology 1997; 113: 478-486.
36. Yamamoto M, Furihata C, Ogiu T et al. Independent variation in susceptibilities of six different mouse strains to induction of pepsinogen-altered pyloric glands and gastric tumor intestinalization by N-methyl-N-nitrosourea. Cancer Lett. 2002; 179: 121-132.
37. Bowles J, Schepers G, Koopman P. Phylogeny of the SOX family of developmental transcription factors based on sequence and structural indicators. Dev. Biol. 2000; 227: 239-255.
38. Wood HB, Episkopou V. Comparative expression of the mouse Sox1, Sox2 and Sox3 genes from pre-gastrulation to early somite stages. Mech. Dev. 1999; 86: 197-201.
39. Sakamoto N, Fukuda K, Watanuki K et al. Role for cGATA-5 in transcriptional regulation of the embryonic chicken pepsinogen gene by epithelial-mesenchymal interactions in the developing chicken stomach. Dev. Biol. 2000; 223: 103-113.
40. Reza HM, Ogino H, Yasuda K. L-Maf, a downstream target of Pax6, is essential for chick lens development. Mech. Dev. 2002; 116: 61-73.
41. Kamachi Y, Uchikawa M, Tanouchi A, Sekido R, Kondoh H. Pax6 and SOX2 form a co-DNA-binding partner complex that regulates initiation of lens development. Genes Dev. 2001; 15: 1272-1286.
42. Kawachi T, Kurisu M, Numanyu N, Sasajima K, Sano T. Precancerous changes in the stomach. Cancer Res. 1976; 36: 2673-2677.
43. Matsukura N, Suzuki K, Kawachi T et al. Distribution of marker enzymes and mucin in intestinal metaplasia in human stomach and relation to complete and incomplete types of intestinal metaplasia to minute gastric carcinomas. J. Natl Cancer Inst. 1980; 65: 231-240.
44. Morson BC. Carcinoma arising from areas of intestinal metaplasia in the gastric mucosa. Br. J. Cancer 1955; 9: 377-385.
45. Filipe MI, Ramachandra S. The histochemistry of intestinal mucins: changes in disease. In Whitehead R eds. Gastrointestinal and oesophageal pathology, 2nd edn. Edinburgh: Churchill Livingstone. 1995: 73-95.
46. Filipe MI, Potet F, Bogomoletz WV et al. Incomplete sulphomucin-secreting intestinal metaplasia for gastric cancer. Preliminary data from a prospective study from three centres. Gut 1985; 26: 1319-1326.
47. Filipe MI, Munoz N, Matko I et al. Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int. J. Cancer 1994; 57: 324-329.
48. Matsukuma A, Mori M, Enjoji M. Sulphomucin-secreting intestinal metaplasia in the human gastric mucosa. An association with intestinal-type gastric carcinoma. Cancer 1990; 66: 689-694.
49. Rokkas T, Filipe MI, Sladen GE. Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up. Gut 1991; 32: 1110-1113.
50. Silva S, Filipe MI. Intestinal metaplasia and its variants in the gastric mucosa of Portuguese subjects: a comparative analysis of biopsy and gastrectomy material. Hum. Pathol 1986; 17: 988-995.
51. You WC, Blot WJ, Li JY et al. Precancerous gastric lesions in a population at high risk of stomach cancer. Cancer Res. 1993; 53: 1317-1321.
52. Stemmermann GN. Intestinal metaplasia of the stomach. A status report. Cancer 1994; 74: 556-564.
53. Kato Y, Kitagawa T, Yanagisawa A et al. Site-dependent development of complete and incomplete intestinal metaplasia types in the human stomach. Jpn. J. Cancer Res. 1992; 83: 178-183.